Home

Differences

This shows you the differences between two versions of the page.

Link to this comparison view

Both sides previous revisionPrevious revision
Next revision
Previous revision
Next revisionBoth sides next revision
home:mp [03.12.2019] – [Endpoints of the Protocol] sallieqhome:mp [03.13.2019] – [Data] sallieq
Line 238: Line 238:
 {{section>:home:patients:mp_duration#after_completion_of_the_marshall_protocol&noheader}} {{section>:home:patients:mp_duration#after_completion_of_the_marshall_protocol&noheader}}
  
-==== Data ==== 
  
-[[home:patients:cohort_statistics#later_information_2013|Success rates for various Dx, compiled in 2013]] 
 ===== Stopping the Protocol ===== ===== Stopping the Protocol =====
  
Line 251: Line 249:
  
 Olmesartan will need to be [[home:mp:break:olmesartan#stopping_olmesartan|weaned very gradually]]. Note that the immune response may remain activated for a period of time even after discontinuing olmesartan. Patients who stop olmesartan are terminating their recovery. Olmesartan will need to be [[home:mp:break:olmesartan#stopping_olmesartan|weaned very gradually]]. Note that the immune response may remain activated for a period of time even after discontinuing olmesartan. Patients who stop olmesartan are terminating their recovery.
 +
 +===== Data =====
 +
 +[[home:patients:cohort_statistics#later_information_2013|Success rates for various Dx, compiled in 2013]]
 +
 +[[home:food:aim_health:aging|Olmesartan research]]
  
 {{tag>MP summary}}   {{tag>MP summary}}  
home/mp.txt · Last modified: 09.14.2022 by 127.0.0.1
© 2015, Autoimmunity Research Foundation. All Rights Reserved.